Ersin Özaslan

Unexpected Foci of Metastasis in a Patient with Thyroid and Breast Cancer: Which One’s Metastasis?

Ayşegül Özdal, Tuğba Uylar Seber, Semra Aytürk, Ersin Özaslan

Thyroid cancer, a common endocrine malignancy, has shown a notable rise in the occurrence in recent times and is commonly linked with breast cancer. While it generally presents a positive prognosis, the cancer’s aggressiveness and the stage at which it is diagnosed …

tr, it (code pays fourni par la source)

Tumor Volume Is a Better Prognostic Factor than Greatest Tumor Diameter in Operated Stage I-III Non–Small-Cell Lung Cancer

Ayşe Ocak Duran, Mevlüde İnanç, Oktay Bozkurt, Ersin Özaslan et autres

tr (code pays fourni par la source)

Association of Early Favipiravir Use with Reduced COVID-19 Fatality among Hospitalized Patients

Ercan Karatas, Laçin Aksoy, Ersin Özaslan

Background: The antiviral agent favipiravir is an RNA-dependent RNA polymerase (RdRp) inhibitor. Materials and Methods: We examined patients with a clinical, laboratory, and radiological diagnosis of severe coronavirus disease 2019 (COVID-19) pneumonia. We investigated the effect of administering enteral favipiravir at a …

tr (code pays fourni par la source)

Is SUVmax of 18F-FDG PET/CT Predictive Factor for Malignancy in Gastrointestinal Tract?

Ersin Özaslan, Melih Kızıltepe, Ümmühan Addulrezzak, Mustafa Kula et autres

ABSTRACT Background: Increasing use of 18 F-FDG PET/CT in cancer patients, has led to more common detection of 18 F-FDG uptake in the gastrointestinal tract (GIT). Aims: The objective of this study was to assess 18 F-FDG uptake in incidental and known …

tr, it (code pays fourni par la source)

The role of primary tumor resection in patients with stage IV colorectal cancer with unresectable metastases.

Semiha Urvay, Tülay Eren, Burak Civelek, Sadettin Kılıçkap et autres

PURPOSE: Whether primary tumor resection (PTR) should be performed in patients with asymptomatic colorectal cancer (CRC) and unresectable synchronous metastasis is controversial. The purpose of this study was to investigate the prognostic impact of initial primary tumor resection in patients with synchronous …

tr (code pays fourni par la source)

Early Onset Favipiravir Saves Lives

Ercan Karatas, Laçin Aksoy, Pinar Elbir Kilic, Arzu Kocagun Dogru et autres

tr, gb (code pays fourni par la source)

Association of Early Favipiravir Use with Reduced COVID-19 Fatality among Hospitalized Patients

Ercan Karatas, Laçin Aksoy, Ersin Özaslan

BACKGROUND: The antiviral agent favipiravir is an RNA-dependent RNA polymerase (RdRp) inhibitor. MATERIALS AND METHODS: We examined patients with a clinical, laboratory, and radiological diagnosis of severe coronavirus disease 2019 (COVID-19) pneumonia. We investigated the effect of administering enteral favipiravir at a …

tr (code pays fourni par la source)

A single-center observational study assessing the predictive factors associated with the prognosis of acromegaly

Halit Diri, Ersin Özaslan, Ali Kurtsoy, Fahrı Bayram

tr (code pays fourni par la source)

Chemotherapy at the End of Life

Semiha Urvay, Burak Civelek, Ersin Özaslan, Aziz Ahmet Sürel

BACKGROUND AND OBJECTIVES: The use of chemotherapy at the end of life in advanced cancer patients has increased and end of life care has become increasingly aggressive. The aim of this study is to evaluate patients receiving chemotherapy in the last 3 …

tr (code pays fourni par la source)

Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study.

Zeynep Oruç, Kaplan Ma, Çağlayan Geredeli, Nilgun Yildirim Sari et autres

PURPOSE: This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients. METHODS: A total of 80 patients treated with eribulin in 12 medical oncology centers in Turkey between …

tr (code pays fourni par la source)

Comorbidity and polypharmacy in patients with breast cancer

Ulaş Serkan Topaloğlu, Ersin Özaslan

tr (code pays fourni par la source)

Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer.

Ersin Özaslan, Ulaş Serkan Topaloğlu, Mevlüde İnanç, Umut Gokmen Erdem et autres

PURPOSE: To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients. METHODS: IPatients were administered cetuximab plus FOLFOX as second- and third-line therapy from January 2010 through October 2015. …

tr (code pays fourni par la source)